Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins

► In vivo production results in effective and persistent levels of therapeutic protein ► Ex vivo modification of cells can be carried out in vitro under controlled conditions ► A cost-effective method would imply the use of stocks of gene-modified allogenic cells ► Encapsulation protects cells from the immune system.